Radiation therapy for clinically localized prostate cancer: A multi- institutional pooled analysis

JAMA

Volumn 281, Issue 17, 1999, Pages 1598-1604

  Shipley, William U ^a   Thames, Howard D ^b   Sandler, Howard M ^b   Hanks, Gerald E ^b   Zietman, Anthony L ^b   Perez, Carlos A ^b   Kuban, Deborah A ^b   Hancock, Steven L ^b   Smith, Cyndi D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

EID: 0033526343     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.17.1598     Document Type: Article

References (27)

1. Zietman AL. Radiation therapy or prostatectomy: an old conflict revisited in the PSA era: a radiation oncologist's viewpoint. Semin Radiat Oncol. 1998;8: 81-86.
2. Klein EA. Radiation therapy vs. radical prostatectomy in the PSA era: a urologist's view. Semin Radiat Oncol. 1998;8:87-94.
3. Middleton RG, Thompson IM, Austenfeld MS, et al, for the Prostate Cancer Clinical Guidelines Panel. Summary of report on the management of clinically localized prostatic cancer. J Urol. 1995;154:2144-2148.
4. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostatic cancer a multi-institutional pooled analysis. JAMA. 1996;276:615-619.
5. Murphy GP, Mettlin C, Menck H. National patterns of prostate treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol. 1994;152:1817-1820.
6. Lu Yao GL, Potosky AL, Albertson PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up cancer treatment after radical prostatectomy: a population based study. J Natl Cancer Inst. 1996;88:166-173.
7. Schellhammer P, Cockett A, Boccon-Gibod L, et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997;49:27-38.
8. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostatic specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-405.
9. Catalona JW, Smith DJ. Five year tumor recurrence rates after anatomic radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837-1842.
10. Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol. 1994; 152:1821-1825.
11. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850-1857.
12. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 1995; 154:456-459.
13. Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA. Stage T1-2 prostate cancer with pre-treatment prostatic specific antigen level less than 10 ng/mL: radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 1997;38:723-729.
14. Zagars GK, Pollack A, von Eschenback AC. Prognostic factors for clinically localized prostate cancer. Cancer. 1997;79:1370-1380.
15. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
16. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al. Results of 3-D conformal radiotherapy in the treatment of localized prostatic cancer. Int J Radiat Oncol Biol Phys. 1997;38:311-318.
17. ASTRO Consensus Statement. Guidelines for PSA following radiation therapy. Int j Radiat Oncol Biol Phys. 1997;37:1035-1041.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 447-457.
19. Cox DR. Regression methods and life tables. J R Stat Soc. 1972;34:187-220.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
21. Breiman L, Freedman JH, Olshen RA, et al. Classification and Regression Trees. New York, NY: Chapman & Hall; 1984.
22. S-Plus Users Manual [computer program]. Version 3.2. Seattle, Wash: Statistical Sciences; 1993.
23. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through PSA based screening. JAMA. 1997;270:948-954.
24. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267:2215-2220.
25. Grignon D, Pajak T, Winter K, et al. Central review vs. institutional Gleason grading and its impact on phase III trial analysis: a review of RTOG protocol 95-31 [abstract]. Mod Pathol. 1997;10:77.
26. Lessel AM, Burnett RA, Howatson SR, et al. Observer variability in the histopathological reporting of needle biopsy specimens of the prostate. Hum Pathol. 1997;28:646-649.
27. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.